U.S. Markets open in 2 hrs 49 mins
  • S&P Futures

    4,684.75
    -14.25 (-0.30%)
     
  • Dow Futures

    35,647.00
    -99.00 (-0.28%)
     
  • Nasdaq Futures

    16,325.25
    -67.00 (-0.41%)
     
  • Russell 2000 Futures

    2,258.20
    -11.60 (-0.51%)
     
  • Crude Oil

    71.93
    -0.43 (-0.59%)
     
  • Gold

    1,783.00
    -2.50 (-0.14%)
     
  • Silver

    22.29
    -0.14 (-0.63%)
     
  • EUR/USD

    1.1325
    -0.0019 (-0.1699%)
     
  • 10-Yr Bond

    1.5090
    0.0000 (0.00%)
     
  • Vix

    20.61
    -1.28 (-5.85%)
     
  • GBP/USD

    1.3190
    -0.0016 (-0.1227%)
     
  • USD/JPY

    113.4790
    -0.2580 (-0.2268%)
     
  • BTC-USD

    49,139.66
    -11.14 (-0.02%)
     
  • CMC Crypto 200

    1,283.13
    -21.99 (-1.69%)
     
  • FTSE 100

    7,325.32
    -11.73 (-0.16%)
     
  • Nikkei 225

    28,725.47
    -135.15 (-0.47%)
     

Looking Into Corcept Therapeutics's Return On Capital Employed

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Looking at Q2, Corcept Therapeutics (NASDAQ: CORT) earned $35.26 million, a 6.49% increase from the preceding quarter. Corcept Therapeutics's sales decreased to $88.56 million, a 5.02% change since Q1. Corcept Therapeutics earned $37.71 million, and sales totaled $93.25 million in Q1.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Corcept Therapeutics posted an ROCE of 0.08%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on CORT

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Corcept Therapeutics's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Q2 Earnings Recap

Corcept Therapeutics reported Q2 earnings per share at $0.32/share, which beat analyst predictions of $0.22/share.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.